Vasculitis & polymyalgia rheumatica

Age at diagnosis influences the clinical phenotype, treatment strategies and outcomes in patients with giant cell arteritis: results from the observational GCAGE study on a large cohort of 1004 patients

Ann Rheum DisPublished Observational cohort study

Authors' conclusion

The highest risk of ischaemic complications, aneurysm development, serious infections and the possible undertreatment make of GCA a very challenging disease in the oldest patients.

Study context

Population
Patients with giant cell arteritis (GCA) followed at referral centres within the Italian Society of Rheumatology Vasculitis Study Group, enrolled up to November 2021mean age 72.1±8.4
Participants
1,004 patients
Exposure
Age at diagnosis ≥80 vs 65-79 vs ≤64 years
Outcome
Blindness
Methodological detailsmulticentre, referral centres
  • Multicentre
  • Referral centres

Main finding

As reported in the abstract

P < 0.0001

Observational data: associations, not effects.

Further findings

Large-vessel-GCA — ≤64
65%

Large-vessel-GCA

More frequent in the youngest group

Relapses · median follow-up 49 (IQR 23-91) months

Relapses occurred in all patients
47%
Age did not influence time to first relapse nor number of relapses

Adjunctive immunosuppressants

Older age negatively associated with number of adjunctive immunosuppressants

Aortic aneurysm/dissection · up to 60 months follow-up

Patients >65 years: increased risk (fold)
2-3

Mortality

Mortality in the population
5.8%
Independent risk factors: age >65, cranial and systemic symptoms

Safety

Treatment-related complications

Serious infections significantly associated with older age
Hypertension, diabetes, osteoporotic fractures not significantly associated with older age

Original publication

Age at diagnosis influences the clinical phenotype, treatment strategies and outcomes in patients with giant cell arteritis: results from the observational GCAGE study on a large cohort of 1004 patients. Ann Rheum Dis. Published 15 May 2023. doi:10.1136/ard-2023-223895

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.